Slide 1: The Transplant Solutions Company
The Transplant Solutions Company Click to edit Master title style Click to edit Master text styles •F E B R U A R Y 2 6 , 2 0 2 5 Patrick G, Kidney Transplant Recipient
Slide 2: Safe Harbor Statement
Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of histor
Slide 3: Q4 and FY 2024 Highlights
Q4 and FY 2024 Highlights Q4 Business Highlights FY 2024 Financial Results Testing Services Volume Growth Revenue • Testing services volume of 45,500, increased 14% • Total full year revenue of $333.8 million increased year-over-year 19% year-over-year • Sixth consecutive quarter of sequential testi
Slide 4: Business Highlights
Business Highlights é CareDx
Slide 5: Achieved Sixth Consecutive Quarter of Testing Services Volume Growth Across All Organs
Achieved Sixth Consecutive Quarter of Testing Services Volume Growth Across All Organs +14% +14% 49.9k 43.7k 44.6k 45.5k 39.9k 42.1k 37.5k 38.4k Q1 20231 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 1. Drop in Testing Services volume from Q1 2023 to Q2 2023 due to the impact of Billing Ar
Slide 6: AlloSeq cfDNA Delivers Highly Accurate dd-cfDNA Testing to Patients Internationally
AlloSeq cfDNA Delivers Highly Accurate dd-cfDNA Testing to Patients Internationally Strong Correlation of the Two Tests • Multicenter prospective study for Detecting the Allograft Kidney Rejection • 580 kidney transplant patients from 2 3 centers in Europe dd-cfDNA (%) p<0.0001 p<0.0001 • AlloSeq cf
Slide 7: Key Drivers of Growth in 2025
Key Drivers of Growth in 2025 H 1 2 0 25 H 2 2 0 25 • Launch AlloSure Heart Peds • Score 7.0 Launch Go to Market • Launch AlloSure SPK • Launch HistoMap Kidney Strategy • XynQAPI IOTA Software Release • AlloView Enhancement • MTM Program Launch • AlloSeq cfDNA publication • KOAR – 1st publication Ev
Slide 8: Financial Highlights
Financial Highlights
Slide 9: CareDx FY 2024 Financial Highlights
CareDx FY 2024 Financial Highlights TESTING NON-GAAP ADJUSTED REVENUE CASH BALANCE* VOLUME GROSS MARGIN1 EBITDA FY 2024 $334 176K 69.4% $27.8M $261 million positive million YEAR- 19% 6% +280 +$65.8M +$26 OVER-YEAR increase increase basis points million 1. Please refer to GAAP to non-GAAP reconciliat
Slide 10: Revenue Growth Across All Businesses
Revenue Growth Across All Businesses Testing Services Patient & Lab Products Digital Solutions +19% +19% +18% +18% $249 +22% +22% $210 $44 in millions USD $41 $37 $34 FY2023 FY2024 FY2023 FY2024 FY2023 FY2024 10
Slide 11: Non-GAAP Gross Margin Improves 280 Basis Points Year-Over-Year
Non-GAAP Gross Margin Improves 280 Basis Points Year- Over-Year +2.8ppt 66.6% 69.4% Drivers of Improved Gross Margin • Testing Services volume growth and ASP expansion • Continued efficiencies in lab operations FY2023 FY2024 11
Slide 12: Operating Leverage and Prudent Expense Management Drives Positive Adjusted EBITDA
Operating Leverage and Prudent Expense Management Drives Positive Adjusted EBITDA +$65.8 $66 $27.8 Drivers of Improved EBITDA in millions USD • Strong revenue growth • Improved gross margin • Lower operating expenses -$38.0 FY2023 FY2024 12
Slide 13: 2025 Guidance
2025 Guidance Revenue Adjusted EBITDA +17% +$21 $370 $31 $334 $28 $316 in millions USD $10 FY2024 FY2024 FY2025 FY2024 FY2024 FY2025 Adjusted* Guidance† Adjusted* Guidance† * FY2024 adjusted revenue and adjusted EBITDA excludes $17 million in revenue associated with tests performed in prior periods
Slide 14: 2025 Guidance
2025 Guidance Guide Assumptions Total Revenue $365M – $375M Testing Services • Volume to grow mid-teens year-over-year • Estimate our ASP to be approximately $1,360 per test on a blended basis • No change to Medicare coverage Products & Patient and Digital Solutions • Mid-teens growth year-over-year
Slide 15: CareDx: Your Partner in Transplant Care
é CareDx’ Your Partner in Transplant Care™ + § CareDae | ossncerownl a
Slide 16: Appendix
Appendix + § CareDae | omssncenon a
Slide 17: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA FY Q1 Q2 Q3 Q4 FY in millions USD 2023 2024 2024 2024 2024 2024 GAAP Net Income (Loss) (190.3) (19.9)(1) (4.6)(1) (10.6)(1) 87.7 52.5 Stock-based compensation expense 49.1 16.5(1) 16.4(1) 16.9(1) 16.5 66.4 Unrealized loss on investments 1.2 - - - - - Realized gain o
Slide 18: Reconciliation of Non-GAAP Gross Margin
Reconciliation of Non-GAAP Gross Margin FY Q1 Q2 Q3 Q4 FY 2023 2024 2024 2024 2024 2024 in millions USD (except %) Revenue 280.3 72.0 92.3 82.9 86.6 333.8 GAAP Cost of Revenue 102.2 25.9 28.0 27.6 28.2 109.7 GAAP Gross Profit 178.1 46.1 64.3 55.3 58.4 224.1 GAAP Gross Margin % 64% 64% 70% 67% 67% 67
Slide 19: The Transplant Solutions Company
The Transplant Solutions Company CO NTAC T U S INVESTOR RELATIONS CORPORATE HQ Caroline Corner 8000 Marina Blvd, investor@caredx.com Brisbane, CA 94005 Click to edit Master title style MEDIA RELATIONS Click to edit Master text styles Anna Czene aczene@caredx.com Kristin J, Stem Cell and Double Lung